Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price & Analysis
Arcturus Therapeutics Holdings Inc. (ARCT) closed at USD 12.15 on Thursday, October 29, 2026, up 0.66% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 12.07; the Oct 29, 2026 session ranged USD 11.94–12.44 on volume of 472,459 shares. Market capitalization is $345.34M, with a 52-week range of USD 5.5–17.96 (NGM). Source: Nexqual, retrieved October 29, 2026 at 23:15 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ARCT.md
Key facts (ARCT)
- Last four reported quarters (through Jun 30, 2026): revenue $29.4M, net income -$93.3M (-317.6% margin), free cash flow -$72.8M (SEC filings).
- Analysts: Buy (mean 2.08 on a 1–5 scale) (13 analysts), mean target USD 23.8 (range 9–41).
- Total return with dividends: 1Y +26.2% vs S&P 500 +14.4%; 5Y -73.0% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.68, revenue estimate $8.0M. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: ARCT paid no cash dividend in the last five years.
- Short interest: 23.90% of float (as of 2026-10-15), 7.0 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ARCT)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $12.4M | $206M | $167M | $152M | $82.0M | $29.4M |
| Operating income | -$203M | $12.2M | -$78.2M | -$95.7M | -$76.3M | -$102M |
| Net income | -$204M | $9.3M | -$29.7M | -$80.9M | -$65.8M | -$93.3M |
| EPS (diluted) | -$7.74 | $0.35 | -$1.12 | -$3.00 | -$2.40 | — |
| Free cash flow | -$138M | $24.3M | -$21.0M | -$60.4M | -$74.5M | -$72.8M |
| Operating margin | -1641.3% | 5.9% | -46.9% | -62.8% | -93.0% | -348.3% |
| Net margin | -1648.0% | 4.5% | -17.8% | -53.1% | -80.2% | -317.6% |
| Revenue growth | +29.6% | +1566.8% | -19.0% | -8.7% | -46.1% | — |
| Cash + short-term investments | $370M | $392M | $292M | $237M | $231M | — |
| Total debt | $63.1M | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ARCT)
P/S 11.8x · P/B 2.0x · FCF yield -21.09% · Earnings yield -27.01%
Analysts (ARCT)
Consensus Buy (mean 2.08 on a 1–5 scale), 13 analysts; mean target USD 23.8 (low 9, high 41).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-09 | Leerink Partners | Target raised | Outperform | $13 → $19 |
| 2026-09-24 | Citigroup | Upgrade | Neutral → Buy | $8 → $20 |
| 2026-09-24 | BTIG | Target lowered | Buy | $23 → $20 |
| 2026-07-02 | Freedom Broker | Initiated | Buy | $27 |
Total return (dividends reinvested) (ARCT)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +26.2% | -73.0% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | +26.3% | -23.0% |
| Volatility (annualized) | 75.7% | 89.1% |
| Max drawdown | -44.5% (Oct 2025→Jul 2026) | -88.2% (Dec 2021→Jul 2026) |
Dividends (ARCT)
ARCT paid no cash dividend in the last five years.
Short interest (ARCT)
5,459,944 shares sold short, 23.90% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 5,467,974 shares (-0.1%). Days to cover: 7.0 (short shares ÷ average daily volume).
ARCT earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 6, 2026 | Quarter ended Jun 30, 2026 | −$0.84 | −$1.03 | Beat +18.4% | +18.4% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | −$0.95 | −$1.01 | Beat +5.9% | +1.0% |
| Mar 3, 2026 | Quarter ended Dec 31, 2025 | −$1.03 | −$0.76 | Miss −35.5% | -9.2% |
| Nov 10, 2025 | Quarter ended Sep 30, 2025 | −$0.49 | −$0.80 | Beat +38.7% | -0.6% |
| Aug 11, 2025 | — | — | — | — | +25.0% |
| May 12, 2025 | — | — | — | — | +8.0% |
| Mar 6, 2025 | — | — | — | — | -9.3% |
| Nov 7, 2024 | — | — | — | — | +7.1% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
ARCT recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 29, 2026 | Schedule 13G/A | Sumitomo Mitsui Trust Group, Inc., Amova Asset Management Co., Ltd.: 5.9% of shares, passive 5%+ holder (amended) |
| Oct 7, 2026 | Schedule 13G/A | Federated Hermes, Inc., Voting Shares Irrevocable Trust: 5.9% of shares, passive 5%+ holder (amended) |
| Sep 23, 2026 | 8-K | Regulation FD disclosure |
| Aug 25, 2026 | 8-K | Regulation FD disclosure |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
| Jul 2, 2026 | 8-K | Entered a material agreement; Regulation FD disclosure “On June 26, 2026, Arcturus Therapeutics, Inc. (" Arcturus "), a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc., a Delaware corporation (the " Company "), entered into a series of agreements with Thermo Fisher Scientific Inc. (" Thermo Fisher ") and certain of Thermo Fisher's affiliates to establish a strategic collaboration for the provision of contract development and manufacturing organization (" CDMO ") and contract research organization (" CRO ") services in connection with the development of…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
ARCT suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | CSL Seqirus | “our compliance, and ability to remain in compliance, with the requirements of our collaboration agreements, including our collaboration with Seqirus Inc. ("CSL Seqirus"), and our ability to prevail in any disputes regarding such collaboration agreements;” |
| Partner | CSL | “In CSL Limited's half-year results presented on February 11, 2026, CSL Limited reported an accounting write-down of approximately $430 million attributable to our collaboration agreement with CSL Seqirus, citing declining COVID-19 disease burden and more onerous U.S. regulatory requirements.” |
| Partner | Meiji Seika Pharma | “In April 2025, our Japanese partner, Meiji, published an analysis characterizing the distribution and clearance of KOSTAIVE (ARCT-154) encoded spike protein and non-structural proteins nsP1, nsP2, nsP3 and nsP4 in the lymph nodes and injection-site muscle in mice following a single vaccination.” |
| Partner | Seqirus | “our compliance, and ability to remain in compliance, with the requirements of our collaboration agreements, including our collaboration with Seqirus Inc. ("CSL Seqirus"), and our ability to prevail in any disputes regarding such collaboration agreements;” |
| Partner | ARCALIS | “We have built a global manufacturing footprint with our partners, including Aldevron, Catalent, Recipharm, Polymun and ARCALIS.” |
| Competitor | Moderna (MRNA) | “We are aware of product candidates of the following companies that we consider as competitors or future competitors to ARCT-032: Moderna/Vertex, Recode Therapeutics, Eloxx Pharmaceuticals, 4DMT, Spirovant, SalioGen, Splisense, Krystal Biotech, Sionna and Enterprise Therapeutics.” |
| Competitor | Pfizer (PFE) | “We consider the following companies with approved or late-stage clinical development vaccines as some of our competitors or future competitors to our partnered COVID-19 vaccine franchise: Pfizer/BioNTech, Moderna, and Sanofi/Novavax.” |
Quoted from the company's 10-K filed Mar 3, 2026.
ARCT company outlook (results filed Aug 6, 2026)
- “The decision to advance ARCT-032 into Phase 3 is expected in Q4 2026, triggering significant resources and support from Thermo Fisher. ·”
- “If Phase 2 yields positive results, Arcturus expects to conduct its Phase 3 program through Thermo Fisher's PPD™ clinical research business.”
Quoted word-for-word from the SEC 8-K results press release.
ARCT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.68 | $-0.88 | +$0.20 | $8.0M | 10 |
| Next quarter (ends Dec 2026) | $-0.93 | $-1.00 | +$0.07 | $5.7M | 10 |
| Current fiscal year (ends Dec 2026) | $-3.45 | $-3.86 | +$0.40 | $18.6M | 10 |
| Next fiscal year (ends Dec 2027) | $-3.70 | $-4.02 | +$0.32 | $28.8M | 10 |
ARCT options: expected move
Options price a move of about ±22.8% (±$2.75) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±9.8% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 111.1% | ±22.8% |
| Dec 18, 2026 | 50 | 100.2% | ±30.3% |
| Mar 19, 2027 | 141 | 97.6% | ±47.9% |
| Jun 17, 2027 | 231 | 102.4% | ±62.2% |
30-day implied volatility 95.2% vs 98.8% realized over the last 30 trading days. Put/call ratio (volume) 0.07. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 23:15 UTC)
| Price | USD 12.15 |
|---|---|
| Change | ▲ 0.66% (up) |
| Previous Close | USD 12.07 |
| Open | USD 12.07 |
| Day Range | USD 11.94 – 12.44 |
| 52-Week Range | USD 5.5 – 17.96 |
| Volume | 472,459 shares |
| Market Cap | $345.34M |
| Exchange | NGM |
Technical Analysis (ARCT)
Nexqual's technical model rates ARCT "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 23:15 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.77 (neutral) |
| vs SMA50 | Below (USD 13.61) |
| MACD | -0.58 (negative) |
Analyst Ratings (ARCT)
Wall Street analysts rate ARCT "Buy" based on 13 analysts, with a mean price target of USD 23.8 (range USD 9–41), per Nexqual as of October 29, 2026 at 23:15 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 23.8 |
| High Target | USD 41 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 11 / 2 / 0 |
Earnings (ARCT)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.68 |
| Revenue Estimate | $8.04M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.84 vs est -1.03 ▲ beat |
| 2026-03-31 | USD -0.95 vs est -1.01 ▲ beat |
| 2025-12-31 | USD -1.03 vs est -0.76 ▼ miss |
| 2025-09-30 | USD -0.49 vs est -0.8 ▲ beat |
Source: Nexqual, October 29, 2026 at 23:15 UTC.
Financials & Fundamentals (ARCT)
| Total Revenue | $29.37M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -89.50% |
| Gross Margin | -195.50% |
| Operating Margin | -863.30% |
| Profit Margin | +0.00% |
| ROE | -46.31% |
| Debt / Equity | 0.13 |
| Current Ratio | 5.88 |
| Total Cash | $191.48M |
| Total Debt | $22.93M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$72.82M (-248.0% of revenue) |
Source: Nexqual, October 29, 2026 at 23:15 UTC.
Financial Health Score (ARCT)
Nexqual rates Arcturus Therapeutics Holdings Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 23:15 UTC.
| Growth | Critical — Revenue -46% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $191M cash vs $23M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$73M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -54%, ROA -41.6% (last 4 quarters, SEC) |
Ownership (ARCT)
| Insider Ownership | +7.99% |
|---|---|
| Institutional Ownership | +77.03% |
| Shares Outstanding | 28.42M |
| Float | 26.15M |
| Short % of Float | +23.90% |
Source: Nexqual, October 29, 2026 at 23:15 UTC.
Leadership (ARCT)
Arcturus Therapeutics Holdings Inc. is led by Joseph E. Payne M.Sc., Founder, President, CEO & Director, per Nexqual as of October 29, 2026 at 23:15 UTC.
| Founder, President, CEO & Director | Joseph E. Payne M.Sc. |
|---|---|
| Founder, Chief Scientific Officer, COO & Secretary | Padmanabh Chivukula |
| Chief Financial Officer | Dennis M. Mulroy |
| Vice President and Head of IR/PR & Marketing | Neda Safarzadeh |
Major Backers & Investors (ARCT)
Notable institutional backers of Arcturus Therapeutics Holdings Inc. include Federated Hermes, Inc., ARK Invest, Sumitomo Mitsui Trust Group, Inc., according to Nexqual as of October 29, 2026 at 23:15 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Federated Hermes, Inc. | 11.62% |
| ARK Invest | 10.21% |
| Sumitomo Mitsui Trust Group, Inc. | 6.91% |
| Amova Asset Management Americas Inc | 6.9% |
| Two Sigma Investments, LP | 3.84% |
| AQR Capital Management, LLC | 2.37% |
| Fidelity | 1.03% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.2% |
| Vanguard Group | 7.27% |
| Geode Capital | 2.44% |
Source: Nexqual, October 29, 2026 at 23:15 UTC.
From Arcturus Therapeutics Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- In December 2022, we entered into a Collaboration and License Agreement ("CSL Collaboration Agreement") with CSL Seqirus, a part of CSL Limited and one of the world's leading influenza vaccine providers, for the global exclusive rights to research, develop, manufacture and commercialize self-amplifying mRNA vaccines against COVID-19, influenza and up to three other infectious diseases and global non-exclusive rights to pandemic pathogens.
- On September 5, 2025, the week prior to the planned Biologics License Application ("BLA") submission related to KOSTAIVE, the FDA requested that the submission of the BLA filing be delayed due to the FDA's expectation of providing additional advice.
- Our proprietary self-amplifying mRNA technology platform, or STARR® ("STARR"), has been demonstrated to induce a robust, longer-lasting and broader humoral immune response at lower dose levels than conventional mRNA-based vaccines.
- Our proprietary LNP delivery system, LUNAR® ("LUNAR"), is intended to address the major hurdle in RNA drug development, namely the effective and safe delivery of RNA to disease-relevant target tissues.
Partnerships
- In our vaccine program, we have partnered with CSL Seqirus, one of the world's leading influenza vaccine providers, on the development and commercialization of mRNA vaccines for COVID-19, influenza and three other infectious diseases.
- In our influenza vaccine franchise, a Phase 1 clinical trial of our seasonal influenza candidate was conducted in 2024-2025 under our collaboration with CSL Seqirus, and a BARDA-funded Phase 1 clinical trial of our H5N1 pandemic flu candidate was initiated in December 2024 and is ongoing.
Legal & Regulatory Risks (Item 1A, quoted)
- Regulatory authorities may change views and recommendations, which could lead to more challenging regulatory paths to approvals and to more expensive clinical and commercial efforts.
- Claims that we infringe the intellectual property rights of others, especially in the crowded and competitive field of mRNA patents, may prevent or delay our development and commercialization efforts.
- We may be involved in lawsuits to protect or enforce our patents or to defend against third party intellectual property claims, which could be expensive, time consuming and unsuccessful.
- We have filed a lawsuit alleging trade secret misappropriation and breach of contract, and any unfavorable outcome or related proceedings could materially and adversely affect our business, financial condition, results of operations, and reputation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.33 | ▼ 0.45% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 23:15 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt